Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Comment by Nohandledzepon Feb 25, 2014 4:32pm
308 Views
Post# 22249935

RE:You heard it here!!!!

RE:You heard it here!!!!
Bad News GMB...You own the one named Bioniche.

Hang tight though. As of next week Bioniche will be 4 months overdue on their "we'll be voting on an Animal Health sale at the AGM".

Interestingly, we are also a mere 4 months out from the maturing of the Paladin loan.

This being Bioniche, they will come up with the worst sale terms possible, or more likely have Urocidin nicely packaged off to Paladin as partial payment for the balance owing.

For their part, Paladin shareholders will be stunned. While we were told that they, as tangible proof of interest in Urocidin,  have taken the rights to NK, Canada and Mexico, most Paladin shareholders have never heard of Urocidin or have any idea what arrangement might exist.

Good for them for hanging tough. It couldn't have been easy loaning money at 20% with those repayment terms and the dire situation with biotech as a whole.
<< Previous
Bullboard Posts
Next >>